Background: The herbal medicine Sairei-to is efficacious in renal diseases where mesangial proliferation is a key event. We examined whether Sairei-to inhibits proliferation of cultured rat mesangial cells and investigated its mechanism of action. Methods: The effect of Sairei-to on [3H]-thymidine incorporation stimulated by serum was assessed. Cell cycle was analyzed by flowcytometry. Extracellular signal-regulated kinase (ERK) activity was determined by immunecomplex kinase assay. Tyrosine phosphorylation of cellular proteins, and phosphorylation of ERK and Raf-1 were analyzed by immunoblot. Cyclic AMP was measured by radioimmunoassay. Results: Incubation of mesangial cells for 18 h with water-soluble but not insoluble fraction of Sairei-to inhibited serum-stimulated [3H]-thymidine incorporation. In subsequent experiments, water-soluble fraction, at a dose required for a half-maximal response (2 mg/ml), was used. Sairei-to inhibited S-phase entry stimulated by serum. Serum-induced tyrosine phosphorylation of p44 and p42 ERK was inhibited by Sairei-to, but that of other cellular proteins was not affected. Suppression of serum-stimulated ERK activation by Sairei-to was confirmed by immunecomplex kinase assay. Activation of Raf-1, an upstream activator of ERK, was also attenuated by Sairei-to. Incubation of cells with Sairei-to significantly increased the generation of cAMP. Conclusions: Sairei-to inhibits serum-induced DNA synthesis of rat mesangial cells by suppressing Raf-1/ERK cascade probably via cAMP.

Cohen B: Herbal remedies and the kidney patient. J Renal Nutr 1998;7:112–114.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M, The Japanese Pediatric IgA Nephropathy Treatment Study Group: A prospective controlled study of Sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Nippon Jinzo Gakkai Shi 1997;39:503–506.
Li P, Kawachi H, Morioka T, Orikasa M, Oite T, Shi ZS, Shimizu F: Suppressive effects of sairei-to on monoclonal antibody 1-22-3-induced glomerulonephritis: Analysis of effective components. Pathol Int 1997;47:430–435.
Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S: Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29:149–160.
Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743–749.
Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, Kojiro M: The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 1994;54:448–454.
Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179–185.
Harper PA, Robinson JM, Hoover RL, Wright TC, Karnovsky MJ: Improved methods for culturing rat glomerular cells. Kidney Int 1984;26:875–880.
Hoshiya M, Awazu M: Trapidil inhibits platelet-derived growth factor-stimulated mitogenactivated protein kinase cascade. Hypertension 1998;31:665–671.
Fabian JR, Daar IO, Morrison DK: Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 1993;13:7170–7179.
Graves LM, Bornfeldt KE, Raines EW, Potts BC, MacDonald SG, Ross R, Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 1993;90:10300–10304.
Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW: Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 1993;262:1065–1069.
Ardaillou N, Nivez MP, Bellon G, Combe C, Ardaillou R: Effect of prostaglandin E2 on proline uptake and protein synthesis by cultured human mesangial cells. Kidney Int 1990;38:1151–1158.
Mene P, Dunn MJ: Prostaglandins and rat glomerular mesangial cell proliferation. Kidney Int 1990;37:1256–1262.
Chini EN, Chini CC, Bolliger C, Jougasaki M, Grande JP, Burnett JC Jr, Dousa TP: Cytoprotective effects of adrenomedullin in glomerular cell injury: Central role of cAMP signaling pathway. Kidney Int 1997;52:917–925.
Matousovic K, Grande JP, Chini CC, Chini EN, Dousa TP: Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 1995;96:401–410.
Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, Pippig S, Lohse M, Ueffing M, Kolch W: Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 1994;14:6696–6703.
Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP: Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types II and IV. J Clin Invest 1996;98:262–270.
Bokemeyer D, Guglielmi KE, McGinty A, Sorokin A, Lianos EA, Dunn MJ: Activation of extracellular signal-regulated kinase in proliferative glomerulonephritis in rats. J Clin Invest 1997;100:582–588.
Bokemeyer D, Ostendorf T, Kunter U, Lindemann M, Kramer HJ, Floege J: Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2000;11:232–240.
Zoja C, Remuzzi G: Role of platelets in progressive glomerular diseases. Pediatr Nephrol 1995;9:495–502.
Geerts A, Rogiers V: Sho-saiko-to: The right blend of traditional Oriental medicine and liver cell biology. Hepatology 1999;29:282–284.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.